Canine leishmaniosis, caused by Leishmania infantum, is a vector-borne disease. The immune response in infected dogs ...

In the long battle to create an effective HIV vaccine, scientists have made a major leap forward. A new study shows that a series of vaccines can coax the immune system to produce powerful ...

Antibody-drug conjugates (ADCs), bispecific antibodies that engage T cells (BsAbs), and chimeric antigen receptor (CAR) T cells are widely used standard-of-care therapies that have revolutionized the ...

Engineering antibodies with a novel fusion protein Fusing two immune system proteins leads to a new method of generating antibodies, opening opportunities for advancing drug discovery ...

The Rise of Bispecific Antibodies: A New Era in Targeted Therapies Traditional monoclonal antibodies (mAbs), primarily immunoglobulin G (IgG), are monospecific, recognizing and binding a single ...

The antibody targets a stable part of the bird flu virus, ensuring that the immune protection can resist new variants and offer long-term protection against the globally spreading airborne infection.

Recombinant antibody production involves the use of recombinant DNA technology to produce an antibody. In this blog post, you will learn all about the process of recombinant antibody production ...

Monoclonal antibodies are a type of synthetic, human-made, antibody. They work similarly to antibodies that the body naturally produces, binding only to specific antigens.

Most people with scleroderma have autoantibodies. Several scleroderma-specific antibodies have been identified. These can help with diagnosis and give insight into the type of disease you may ...

Researchers led by teams at NYU Langone Health and its Perlmutter Cancer Center have reported on the development of antibodies that can selectively target cancer-related mutations in the ...

Artificial intelligence simultaneously balances multiple antibody attributes—from affinity to manufacturability—to speed antibody therapeutics to the clinic.